StockpollyBeta
Get App
Popularity #1,738
NUVB · NYSE · Biotechnology

Nuvation Bio (NUVB)

Develops cancer medicines led by IBTROZI and a focused oncology pipeline.

$6.10
After hours0.00 (0.00%)
At close$6.10(+0.49%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0001163513428332
Cost of revenue000124233061
Gross profit0000−111210417831
2621204704755606666757482
Research & development1915134542829252729343531
857162026353837403843
Selling & marketing000011011000
General & administrative857161925038370043
Other expenses000000000109
Operating income−26−21−20−470−48−54−59−64−56−344−51
775874651−32−12
Interest income777776556555
Interest expense000000007777
Other non-operating income−7−7−5−8−7−5−6−5−1−4−85
Income before tax−20−14−15−462−41−49−53−59−56−375−63
Net income from continuing operations−20−14−15−462−41−49−53−59−56−375−63
Net income−20−14−15−462−41−49−53−59−56−375−63
EPS, basic−$0.09−$0.06−$0.07−$1.89−$0.15−$0.15−$0.16−$0.17−$0.16−$0.11$0.02−$0.18
EPS, diluted−$0.09−$0.06−$0.07−$1.89−$0.15−$0.15−$0.16−$0.17−$0.16−$0.11$0.01−$0.18
Weighted average shares, basic219219219245274337339341342344347349
Weighted average shares, diluted219219219245274337339341342344378349
EBITDA−20−14−15−462−41−49−53−58−55−2913−56
Depreciation & amortization000000001111
EBIT−20−14−15−462−41−49−53−59−55−3012−56